| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $44.8M | -18.9% |
| SG&A Expense | $18.7M | +3.9% |
| Operating Income | -$63.6M | +13.3% |
| Income Tax | $0 | — |
| Net Income | -$58.2M | +11.0% |
| EPS (Basic) | -$2.60 | +32.5% |
| EPS (Diluted) | -$2.60 | +32.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $17.9M | -32.8% |
| Short-term Investments | $89.7M | -28.5% |
| Current Assets | $109.6M | -29.0% |
| Total Assets | $157.1M | -23.9% |
| Current Liabilities | $12.5M | +54.1% |
| Total Liabilities | $58.4M | +4.7% |
| Stockholders' Equity | $98.7M | -34.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$46.7M | +23.3% |
| Capital Expenditures | $546K | -78.5% |
| Investing Cash Flow | $37.8M | +244.8% |
| Financing Cash Flow | $141K | -99.8% |
| Free Cash Flow | -$47.2M | +25.5% |